- MRK Q2 sales $16.6B (+5% YoY), Keytruda $8.4B, Winrevair $588M (+75%). GAAP net loss $1.34B; adjusted loss $0.13/sh due to $5.7B acquisition charge. 2026 sales guide $66.3–67.3B; adj EPS $2.66–2.76.
- Merck (MRK) advances sac-TMT, an ADC targeting Trop-2 in multiple Phase 3 cancer trials; company calls it a cornerstone that could reshape KEYNOTE-189–style lung cancer combination strategies
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.